NCT02773030 2026-03-20
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
Clinical Trials
16 trialsNCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT03989414 2024-11-29
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
Phase 1/2 Active not recruiting
NCT03643549 2024-02-29
BORTEM-17
Haukeland University Hospital
Phase 1/2 Unknown
NCT05408026 2023-01-27
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
Phase 1/2 Withdrawn
NCT02356458 2022-03-11
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 1/2 Terminated
NCT00708292 2020-12-17
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Novartis
Phase 1/2 Completed
NCT00903968 2020-06-02
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01504477 2020-03-16
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Georgetown University
Phase 1/2 Terminated
NCT00440726 2020-02-19
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Completed
NCT01672736 2018-09-13
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
University Health Network, Toronto
Phase 1/2 Terminated
NCT00401011 2018-02-23
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
AEterna Zentaris
Phase 1/2 Completed
NCT00651781 2013-02-28
Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia
PETHEMA Foundation
Phase 1/2 Completed
NCT00536575 2013-02-27
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00752518 2011-05-17
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
Janssen Pharmaceutical K.K.
Phase 1/2 Completed
NCT00352742 2008-10-28
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
Attenuon
Phase 1/2 Terminated